Annexin Pharmaceuticals AB Stock
Stocks
ANNX
SE0025159387
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.85 SEK | -0.39% |
|
-1.15% | -35.10% |
| Market Cap | 90.71M 9.34M 8.2M 7.6M 7M 13.22M 893M 13.5M 35.5M 438M 35.05M 34.3M 1.53B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 90.71M 9.34M 8.2M 7.6M 7M 13.22M 893M 13.5M 35.5M 438M 35.05M 34.3M 1.53B | EV / Sales 2026 * |
1.2x | EV / Sales 2027 * | - |
| Free-Float |
23.86% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -0.39% | ||
| 1 week | -1.15% | ||
| Current month | +6.64% | ||
| 1 month | +4.47% | ||
| 3 months | -6.20% | ||
| 6 months | -28.61% | ||
| Current year | -35.10% |
| 1 week | 11.9 |  | 13.25 |
| 1 month | 11.05 | | 13.25 |
| Current year | 11.05 | | 23.6 |
| 1 year | 11.05 | | 35.8 |
| 3 years | 11.05 | | 109 |
| 5 years | 11.05 | | 225 |
| 10 years | 11.05 | | 1,320 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2018-12-31 | |
Anna Frostegård
CTO | Chief Tech/Sci/R&D Officer | 53 | 2015-12-31 |
| Director of Finance/CFO | 55 | 2023-04-10 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 50 | 2016-12-31 | |
| Director/Board Member | 73 | - | |
Jan Nilsson
CHM | Chairman | 77 | 2023-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.39% | -1.15% | -55.07% | -87.15% | 9.45M | |
| -2.48% | -3.13% | +55.85% | +89.65% | 54.88B | |
| -0.55% | -8.57% | +58.09% | +124.47% | 54.63B | |
| -5.60% | -2.20% | +11.16% | +437.37% | 25.06B | |
| -1.55% | -7.66% | -20.21% | -17.37% | 23.14B | |
| -1.69% | -0.64% | +40.04% | -0.48% | 19.87B | |
| +1.87% | +1.87% | +38.13% | -26.14% | 17.55B | |
| -2.72% | -0.60% | +187.08% | +351.91% | 16.5B | |
| -2.42% | +1.00% | +48.24% | +635.77% | 15.75B | |
| -0.81% | +0.34% | +24.92% | +189.31% | 14.2B | |
| Average | -1.63% | -0.81% | +38.82% | +169.73% | 24.16B | |
| Weighted average by Cap. | -1.81% | -1.56% | +48.50% | +166.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 75.6M 7.78M 6.83M 6.34M 5.83M 11.02M 744M 11.25M 29.59M 365M 29.21M 28.59M 1.27B | - |
| Net income | 19.6M 2.02M 1.77M 1.64M 1.51M 2.86M 193M 2.92M 7.67M 94.71M 7.57M 7.41M 330M | -58M -5.97M -5.24M -4.86M -4.47M -8.45M -571M -8.63M -22.7M -280M -22.41M -21.93M -978M |
| Net Debt | - | - |
Employees
4
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-13 | SEK 12.85 | -0.39% | 2,149 |
| 26-07-10 | SEK 12.90 | -1.90% | 4,875 |
| 26-07-09 | SEK 13.15 | +3.14% | 3,443 |
| 26-07-08 | SEK 12.75 | +3.66% | 9,709 |
| 26-07-07 | SEK 12.30 | -1.20% | 18,780 |
Net sales - Rate of surprise
- Stock Market
- Stocks
- ANNX Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
